Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ONC

BeiGene Ltd. ADR

Mar 11 • 04:00PM ET

245.71

Dollar change +3.05
Percentage change 1.26	%

Healthcare • Biotechnology • Cayman Islands • NASD

Peers: REGN AMGN VRTX GILD INCY BMRN EXEL KPTI IONS BLUE

| Held by: IBB FBT BBH ONEQ AVEM FTHI CANC FFTY TSPA CGIE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.13	Insider Own	1.05%	Shs Outstand	97.63M	Perf Week	-4.51%
Market Cap	24.20B	Forward P/E	44.99	EPS next Y	5.46	Insider Trans	-95.11%	Shs Float	97.45M	Perf Month	9.94%
Income	-644.79M	PEG	-	EPS next Q	-0.46	Inst Own	43.06%	Short Float	1.52%	Perf Quarter	21.84%
Sales	3.81B	P/S	6.35	EPS this Y	117.70%	Inst Trans	-10.32%	Short Ratio	3.43	Perf Half Y	28.43%
Book/sh	31.22	P/B	7.87	EPS next Y	404.92%	ROA	-10.99%	Short Interest	1.48M	Perf Year	51.44%
Cash/sh	26.77	P/C	9.18	EPS next 5Y	-	ROE	-18.77%	52W Range	126.97 - 287.88	Perf YTD	33.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	17.26%	ROI	-18.20%	52W High	-14.65%	Beta	0.54
Dividend TTM	-	Quick Ratio	1.58	Sales past 5Y	80.39%	Gross Margin	81.01%	52W Low	93.52%	ATR (14)	10.64
Dividend Ex-Date	-	Current Ratio	1.80	EPS Y/Y TTM	27.50%	Oper. Margin	-14.91%	RSI (14)	52.10	Volatility	3.29% 3.82%
Employees	11000	Debt/Eq	0.32	Sales Y/Y TTM	54.96%	Profit Margin	-16.92%	Recom	1.16	Target Price	333.70
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	59.53%	Payout	-	Rel Volume	0.86	Prev Close	242.66
Sales Surprise	7.94%	EPS Surprise	-41.28%	Sales Q/Q	77.78%	Earnings	Feb 27 BMO	Avg Volume	431.41K	Price	245.71
SMA20	-0.92%	SMA50	10.33%	SMA200	25.90%	Trades		Volume	373,044	Change	1.26%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-03-25	Upgrade	BofA Securities	Neutral → Buy	$207 → $320
Dec-03-24	Resumed	Morgan Stanley	Overweight	$300
Sep-18-24	Initiated	JMP Securities	Mkt Outperform	$288
Feb-06-24	Resumed	JP Morgan	Overweight	$185
Sep-12-23	Initiated	Macquarie	Outperform	$259
Aug-17-23	Initiated	Jefferies	Buy	$287
Jul-17-23	Initiated	Citigroup	Buy	$275
Jun-30-23	Downgrade	Bernstein	Outperform → Mkt Perform	$335 → $196
Jan-12-23	Initiated	Daiwa Securities	Buy	$308
Oct-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$177 → $200
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$205
Aug-09-22	Resumed	JP Morgan	Overweight	$296
Mar-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$300 → $177
Feb-07-22	Initiated	Deutsche Bank	Buy
Oct-12-21	Initiated	Bernstein	Outperform	$431
Oct-06-21	Upgrade	CLSA	Underperform → Buy
Mar-08-21	Initiated	China Renaissance	Buy
Mar-01-21	Downgrade	CLSA	Outperform → Underperform	$330 → $321
Nov-09-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-06-20	Downgrade	Piper Sandler	Neutral → Underweight	$175 → $185

Show Previous Ratings

Mar-06-25 11:12AM	Q4 2024 Zymeworks Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-25 04:54AM	FDA approves BeiGenes Tevimbra plus chemo for oesophageal cancer (Pharmaceutical Technology)
Mar-04-25 06:00AM	TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy (Business Wire)
Mar-02-25 11:52AM	Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025 (Insider Monkey)
Mar-01-25 02:42PM	Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now? (Insider Monkey)
09:30AM	Loading…
Feb-27-25 09:30AM	BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +7.48%
06:00AM	BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates (Business Wire)
Feb-25-25 06:01AM	BeiGene to Present at Upcoming Investor Conferences (Business Wire)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily)
03:24AM	BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock? (Zacks)
Feb-13-25 06:01AM	BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27 (Business Wire)
Jan-30-25 04:23AM	ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo (Clinical Trials Arena)
Jan-15-25 03:44PM	BeiGene Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
08:57AM	BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last? (Zacks)
Jan-06-25 02:00AM	BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe (Business Wire)
06:54AM	Loading…
Dec-30-24 06:54AM	FDA approves BeiGene's TEVIMBRA combo for treating certain gastric cancers (Pharmaceutical Business Review)
06:42AM	BeiGenes Tevimbra approved in US for first-line gastric cancer treatment (Pharmaceutical Technology)
Dec-27-24 06:00AM	TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy (Business Wire)
Dec-23-24 06:00AM	BeiGene to Change Nasdaq Ticker Symbol to ONC on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 09:12AM	BeiGene inks $150M deal to follow cancer combo trail blazed by Amgen and Ideaya (FierceBiotech.com)
Dec-12-24 07:30PM	BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor (Business Wire)
Dec-09-24 08:30PM	BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets (Business Wire) -9.69%
Dec-04-24 06:00AM	BeiGene and CLL Society Partner to Advance Test Before Treat Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL (Business Wire)
Dec-03-24 04:00PM	BeiGene Gains Overweight Rating from Morgan Stanley with $300 Price Target (GuruFocus.com)
Dec-02-24 04:08PM	Why Is BeiGene, Ltd. (BGNE) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
06:01AM	BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 (Business Wire)
Nov-27-24 12:25PM	BeiGenes PD-1 drug approved in EU for first-line oesophageal cancer treatment (Pharmaceutical Technology) +7.31%
12:01PM	Why Is BeiGene Stock Trading Higher On Wednesday? (Benzinga)
06:00AM	European Commission Approves BeiGenes TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer (Business Wire)
Nov-26-24 06:01AM	BeiGene to Present at Upcoming Investor Conferences (Business Wire)
07:00AM	Loading…
Nov-19-24 07:00AM	Labcorp CFO Glenn Eisenberg Announces Plans to Retire (PR Newswire)
06:00AM	BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA (Business Wire)
Nov-15-24 12:20PM	BeiGene, Ltd. (BGNE): Among 12 High Growth Large Cap Stocks to Buy Now (Insider Monkey)
05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
Nov-14-24 06:00AM	BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer (Business Wire)
Nov-13-24 12:12AM	Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight (GuruFocus.com)
Nov-12-24 06:00AM	BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates (Business Wire) -5.56%
Nov-06-24 06:01AM	BeiGene to Present at the Jefferies London Healthcare Conference (Business Wire)
Nov-05-24 09:05AM	BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 (Business Wire)
Oct-28-24 06:00AM	BeiGene Mourns Death of Beloved Board Member Donald Glazer (Business Wire)
Oct-21-24 06:00AM	BeiGene Receives Positive CHMP Opinions for TEVIMBRA as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma (Business Wire)
Oct-16-24 06:00AM	BeiGene Highlights Waldenstrms Macroglobulinemia Innovation at IWWM 2024 (Business Wire)
Oct-10-24 10:09AM	Heres Why BeiGene, Ltd. (BGNE) Rallied in Q3 (Insider Monkey)
Oct-07-24 05:04AM	BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? (Zacks)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +5.31%
Sep-26-24 06:21PM	BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA, for Treatment of ESCC and Gastric/GEJ Cancers (Business Wire)
06:00AM	Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors (Business Wire)
Sep-25-24 03:54PM	FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients (Benzinga)
Sep-18-24 04:12AM	BeiGenes TEVIMBRA gains approval for OSCC in Israel (Pharmaceutical Technology)
Sep-17-24 07:00AM	BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy (Business Wire)
Sep-12-24 09:00PM	BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk (PR Newswire) -7.05%
Sep-09-24 07:00AM	BeiGene Announces Updates to Commercial Leadership Team (Business Wire)
01:00AM	BeiGene Highlights TEVIMBRA Data in Lung and Gastrointestinal Cancers at ESMO 2024 (Business Wire)
Aug-28-24 09:55AM	Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High? (Zacks)
06:01AM	BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-27-24 08:23AM	FDA grants fast track status to BeiGenes BGB-16673 for CLL/SLL (Pharmaceutical Technology)
Aug-26-24 09:55AM	BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
06:00AM	BeiGenes BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL (Business Wire)
Aug-23-24 02:10PM	Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer (Benzinga)
Aug-12-24 09:55AM	Wall Street Analysts See a 40.85% Upside in BeiGene (BGNE): Can the Stock Really Move This High? (Zacks)
Aug-08-24 01:05AM	Beyond the Balance Sheet: What SWOT Reveals About BeiGene Ltd (BGNE) (GuruFocus.com)
Aug-07-24 06:00AM	BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates (Business Wire)
Aug-01-24 04:12AM	NICE recommends BeiGenes MZL tablet for NHS use (Pharmaceutical Technology)
Jul-24-24 06:33AM	BeiGene opens biologics facility in New Jersey, US (Pharmaceutical Technology)
Jul-23-24 07:00AM	BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World (Business Wire)
Jul-18-24 06:30AM	BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer (Business Wire)
Jun-27-24 03:16AM	Insider Sale: CFO Julia Wang Sells Shares of BeiGene Ltd (BGNE) (GuruFocus.com)
Jun-21-24 03:09AM	Insider Sale: CFO Julia Wang Sells Shares of BeiGene Ltd (BGNE) (GuruFocus.com)
Jun-14-24 06:00AM	BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 (Business Wire)
Jun-13-24 07:41PM	BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region (Business Wire)
Jun-04-24 06:01AM	BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) +6.05%
May-29-24 07:07AM	7 Large-Cap Stocks That Can Jump 50% By 2025 (InvestorPlace)
May-28-24 08:00AM	BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study (GlobeNewswire)
May-24-24 06:00AM	BRUKINSA Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL (Business Wire)
May-22-24 01:38AM	European Banks M&A Cross-Border Transactions Unlikely, Citi Says (The Wall Street Journal)
May-21-24 09:36PM	Indias Sensex Up 0.2%, Led by Industrial, Consumer Stocks (The Wall Street Journal)
09:36PM	Hong Kong Shares Open Flat; Tech Weakness Persists (The Wall Street Journal)
07:21AM	Glenmark to market BeiGenes oncology medicines in India (Pharmaceutical Technology)
12:33AM	Nikkei Falls 0.3%, Dragged by Real-Estate, Machinery Stocks (The Wall Street Journal)
12:33AM	Hong Kong Shares Extend Losses at Midday Amid Profit Taking (The Wall Street Journal)
May-20-24 01:13PM	BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why (Zacks)
May-14-24 04:01PM	BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 (Business Wire)
May-09-24 01:05AM	Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight (GuruFocus.com)
May-08-24 09:55PM	Indias Sensex Down 0.4%, Dragged by Industrial, Tech Stocks (The Wall Street Journal)
09:55PM	Hong Kong Shares Rise 0.3%, Led by Tech Hardware, Pharma Stocks (The Wall Street Journal)
01:54PM	BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:18AM	Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday (MT Newswires)
06:40AM	BeiGene's Q1 Loss Narrows as Revenue Rises (MT Newswires)
06:00AM	BeiGene Reports First Quarter 2024 Financial Results and Business Updates (Business Wire)
Apr-29-24 09:50AM	10 Most Promising Stocks to Buy Before They Take Off (Insider Monkey)
Apr-26-24 10:34AM	BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report (Business Wire)
Apr-25-24 09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
08:53AM	20 Countries with the Highest Rates of Stomach Cancer in the World (Insider Monkey)
Apr-24-24 04:01PM	Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting (Business Wire)
Apr-23-24 09:19AM	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer (MT Newswires) +6.15%
06:00AM	BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer (Business Wire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 04:28PM	BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy (Business Wire)
02:54PM	UPDATE 1-US FDA approves BeiGene's esophageal cancer therapy (Reuters)
02:14PM	US FDA approves BeiGene's esophageal cancer therapy (Reuters)

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JOHN OYLER	Officer	Mar 10 '25	Proposed Sale	242.67	41,210	10,000,480		Mar 10 04:19 PM
OYLER JOHN	Chief Executive Officer	Mar 07 '25	Option Exercise	0.96	767,337	735,208	5,600,803	Mar 07 08:17 PM
OYLER JOHN	Chief Executive Officer	Mar 07 '25	Sale	249.13	58,590	14,596,247	0	Mar 07 08:17 PM
OYLER JOHN	Chief Executive Officer	Mar 06 '25	Option Exercise	0.96	526,270	503,789	4,892,056	Mar 07 07:26 PM
OYLER JOHN	Chief Executive Officer	Mar 06 '25	Sale	259.15	40,109	10,394,329	0	Mar 07 07:26 PM
Wu Xiaobin	President, COO & GM China	Mar 05 '25	Option Exercise	126.71	51,921	6,578,658	51,921	Mar 07 07:24 PM
Wu Xiaobin	President, COO & GM China	Mar 05 '25	Sale	261.59	51,921	13,581,905	0	Mar 07 07:24 PM
JOHN OYLER	Officer	Mar 07 '25	Proposed Sale	249.13	58,590	14,596,245		Mar 07 05:14 PM
JOHN OYLER	Officer	Mar 06 '25	Proposed Sale	259.15	40,109	10,394,328		Mar 06 05:22 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Mar 04 '25	Sale	254.58	8,146	2,073,826	0	Mar 06 04:48 PM
OYLER JOHN	Chief Executive Officer	Mar 03 '25	Option Exercise	0.96	1,321,531	1,266,766	4,199,364	Mar 05 04:59 PM
OYLER JOHN	Chief Executive Officer	Mar 03 '25	Sale	244.30	101,000	24,674,638	0	Mar 05 04:59 PM
XIAOBIN WU	Officer	Mar 05 '25	Proposed Sale	257.31	51,921	13,359,793		Mar 05 04:26 PM
WANG INVESTMENT LLC	Co-Founder	Mar 04 '25	Proposed Sale	245.53	8,146	2,000,087		Mar 04 05:07 PM
HHLR Advisors, Ltd. (1)	Shareholder (1)	Mar 03 '25	Proposed Sale	271.80	2,480,000	674,064,000		Mar 03 09:31 PM
JOHN OYLER	Officer	Mar 03 '25	Proposed Sale	244.30	101,000	24,674,633		Mar 03 05:30 PM
Lee Chan Henry	SVP, General Counsel	Feb 27 '25	Sale	275.00	1,205	331,375	0	Mar 03 04:49 PM
Baker Brothers Life Sciences,	Affiliate	Feb 28 '25	Proposed Sale	260.00	671,976	174,713,760		Feb 28 09:43 PM
667, L.P.	Affiliate	Feb 28 '25	Proposed Sale	260.00	60,851	15,821,260		Feb 28 09:40 PM
BAKER BROS. ADVISORS LP	Director	Feb 28 '25	Sale	260.00	732,827	190,535,020	730,642	Feb 28 09:28 PM
CHAN LEE	Officer	Feb 27 '25	Proposed Sale	259.00	1,205	312,095		Feb 27 04:27 PM
Wang Lai	Global Head of R&D	Feb 21 '25	Sale	257.23	5,000	1,286,174	0	Feb 25 05:06 PM
Lee Chan Henry	SVP, General Counsel	Feb 21 '25	Sale	258.04	1,202	310,170	0	Feb 25 05:04 PM
CHAN LEE	Officer	Feb 21 '25	Proposed Sale	244.20	1,202	293,528		Feb 21 04:24 PM
WANG HOLDINGS LLC	Officer	Feb 21 '25	Proposed Sale	244.20	5,000	1,221,000		Feb 21 04:23 PM
Wu Xiaobin	President, COO & GM China	Feb 18 '25	Option Exercise	169.65	30,654	5,200,451	30,654	Feb 20 06:12 PM
Wu Xiaobin	President, COO & GM China	Feb 20 '25	Option Exercise	169.65	21,267	3,607,947	21,267	Feb 20 06:12 PM
Wu Xiaobin	President, COO & GM China	Feb 18 '25	Sale	240.74	30,654	7,379,531	0	Feb 20 06:12 PM
Wu Xiaobin	President, COO & GM China	Feb 20 '25	Sale	240.07	21,267	5,105,513	0	Feb 20 06:12 PM
XIAOBIN WU	Officer	Feb 18 '25	Proposed Sale	230.86	51,921	11,986,482		Feb 18 04:29 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Feb 04 '25	Option Exercise	6.50	41,760	271,440	41,760	Feb 06 04:44 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Feb 04 '25	Sale	225.69	41,760	9,424,955	0	Feb 06 04:44 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jan 07 '25	Option Exercise	6.50	41,760	271,440	41,760	Jan 08 05:08 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jan 07 '25	Sale	176.50	41,760	7,370,515	0	Jan 08 05:08 PM
XIAODONG WANG	Director	Jan 07 '25	Proposed Sale	180.64	125,280	22,630,579		Jan 07 04:18 PM
OYLER JOHN	Chief Executive Officer	Dec 14 '24	Option Exercise	0.50	1,300,000	650,000	2,978,833	Dec 17 05:02 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Dec 10 '24	Option Exercise	6.50	41,760	271,440	41,760	Dec 12 05:18 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Dec 10 '24	Sale	186.90	41,760	7,805,106	0	Dec 12 05:18 PM
BAKER BROS. ADVISORS LP	Director	Dec 09 '24	Sale	187.27	1,037,017	194,200,043	791,493	Dec 10 09:25 PM
XIAODONG WANG	Director	Dec 10 '24	Proposed Sale	207.62	41,760	8,670,211		Dec 10 04:26 PM
667, L.P.	Affiliate	Dec 09 '24	Proposed Sale	187.27	86,110	16,125,648		Dec 09 09:48 PM
Baker Brothers Life Sciences,	Affiliate	Dec 09 '24	Proposed Sale	187.27	950,907	178,074,395		Dec 09 09:48 PM
HHLR ADVISORS, LTD.	10% Owner	Dec 02 '24	Sale	200.00	17,842,500	3,568,500,000	125,045,741	Dec 04 04:06 PM
HHLR Advisors, Ltd. (1)	Shareholder (1)	Dec 02 '24	Proposed Sale	215.00	1,372,500	295,087,500		Dec 02 09:45 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 26 '24	Option Exercise	6.50	38,461	249,996	40,468	Nov 29 04:31 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 26 '24	Sale	190.10	40,468	7,693,071	0	Nov 29 04:31 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 26 '24	Sale	189.97	7,883	1,497,499	0	Nov 29 04:31 PM
XINSHENG LIAO TTEE XIAODONG WA	Officer	Nov 26 '24	Proposed Sale	190.30	7,883	1,500,135		Nov 26 04:23 PM
XIAODONG WANG	Director	Nov 26 '24	Proposed Sale	190.30	40,468	7,701,060		Nov 26 04:23 PM
PAN-OYLER FOUNDATION	Director	Nov 25 '24	Proposed Sale	190.51	1,969	375,114		Nov 25 04:39 PM
OYLER JOHN	Chief Executive Officer	Oct 08 '24	Sale	232.22	10,000	2,322,161	0	Oct 10 05:48 PM
OYLER JOHN	Chief Executive Officer	Oct 08 '24	Sale	232.22	6,175	1,433,931	0	Oct 10 05:48 PM
JOHN F OYLER	Director	Oct 08 '24	Proposed Sale	243.02	6,175	1,500,648		Oct 08 04:24 PM
OYLER INVESTMENT LLC	Director	Oct 08 '24	Proposed Sale	243.02	10,000	2,430,200		Oct 08 04:23 PM
Lee Chan Henry	SVP, General Counsel	Sep 30 '24	Sale	237.10	1,202	284,994	0	Oct 02 07:13 PM
Wang Lai	Global Head of R&D	Sep 27 '24	Sale	220.35	5,000	1,101,774	0	Oct 01 06:29 PM
CHAN LEE	Officer	Sep 30 '24	Proposed Sale	218.42	1,202	262,541		Sep 30 04:27 PM
WANG HOLDINGS LLC	Officer	Sep 27 '24	Proposed Sale	212.53	5,000	1,062,650		Sep 27 04:25 PM
Wu Xiaobin	President, COO & GM China	Sep 19 '24	Sale	200.14	4,500	900,615	0	Sep 19 05:25 PM
Wu Xiaobin	President, COO & GM China	Sep 17 '24	Sale	200.00	500	100,000	4,500	Sep 19 05:25 PM
XIAOBIN WU	Officer	Sep 17 '24	Proposed Sale	196.45	5,000	982,250		Sep 17 04:40 PM
Wu Xiaobin	President, COO & GM China	Sep 03 '24	Sale	189.65	5,556	1,053,677	0	Sep 05 05:41 PM
Ball Titus B.	Principal Accounting Officer	Sep 03 '24	Sale	189.94	137	26,022	0	Sep 05 05:40 PM
AIJUN WANG	Officer	Sep 03 '24	Proposed Sale	190.08	3,160	600,661		Sep 03 05:00 PM
XIAOBIN WU	Officer	Sep 03 '24	Proposed Sale	191.78	5,556	1,065,530		Sep 03 04:19 PM
PAN-OYLER FOUNDATION	Director	Aug 27 '24	Proposed Sale	199.22	1,883	375,131		Aug 27 04:30 PM
Lee Chan Henry	SVP, General Counsel	Jul 30 '24	Sale	160.57	834	133,915	0	Aug 01 05:06 PM
CHAN LEE	Officer	Jul 30 '24	Proposed Sale	160.57	834	133,915		Jul 30 04:15 PM
Wang Julia Aijun	Chief Financial Officer	Jul 01 '24	Sale	143.90	472	67,919	0	Jul 03 05:05 PM
Wang Julia Aijun	Chief Financial Officer	Jun 24 '24	Sale	155.66	899	139,938	0	Jun 26 05:26 PM
Wang Lai	Global Head of R&D	Jun 24 '24	Sale	159.80	1,064	170,030	0	Jun 26 05:25 PM
Wu Xiaobin	President, COO & GM China	Jun 24 '24	Sale	159.79	1,459	233,133	0	Jun 26 05:24 PM
OYLER JOHN	Chief Executive Officer	Jun 24 '24	Sale	159.58	2,789	445,070	0	Jun 26 05:22 PM
OYLER JOHN	Chief Executive Officer	Jun 17 '24	Sale	159.35	1,281	204,125	0	Jun 20 05:27 PM
Wang Julia Aijun	Chief Financial Officer	Jun 17 '24	Sale	159.04	916	145,678	0	Jun 20 05:26 PM
Wang Lai	Global Head of R&D	Jun 17 '24	Sale	159.24	1,500	238,857	841	Jun 20 05:25 PM
Wang Lai	Global Head of R&D	Jun 18 '24	Sale	153.75	841	129,305	0	Jun 20 05:25 PM
Wu Xiaobin	President, COO & GM China	Jun 18 '24	Sale	154.36	2,627	405,516	0	Jun 20 05:25 PM
Wu Xiaobin	President, COO & GM China	Jun 17 '24	Sale	159.00	627	99,692	2,627	Jun 20 05:25 PM
Lee Chan Henry	SVP, General Counsel	Jun 17 '24	Sale	159.35	439	69,955	0	Jun 20 05:24 PM
OYLER JOHN	Chief Executive Officer	Apr 10 '24	Sale	148.89	26,716	3,977,861	12,084	Apr 11 06:01 PM
OYLER JOHN	Chief Executive Officer	Apr 11 '24	Sale	146.73	12,084	1,773,085	0	Apr 11 06:01 PM
OYLER JOHN	Chief Executive Officer	Apr 09 '24	Sale	153.94	11,200	1,724,078	38,800	Apr 11 06:01 PM
OYLER JOHN	Chief Executive Officer	Mar 13 '24	Sale	177.56	12,332	2,189,648	0	Mar 14 05:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONC

BeiGene Ltd. ADR

Upgrade your FINVIZ experience